Prostatype Genomics announces outcome of exercise of warrants of series 3 (TO3)
Prostatype Genomics AB ("Prostatype Genomics" or the "Company") today announces the outcome of the exercise period for warrants of series 3 (the "Warrants" or “TO3”) issued in connection with Prostatype Genomics rights issue of units announced on 7 November 2023 (the “Rights Issue”). A total of 202,524,736 Warrants were exercised, of which 20,000,000 by offsetting claims, corresponding to a subscription rate of approximately 81.0 percent. Prostatype Genomics receives proceeds of approximately SEK 7.3 million before issuing costs.
“We have recently announced several important advances for the Company’s market activities in the United States and our ongoing studies, and the high subscription rate shows strong support for our imminent US market entry. I want to thank everyone who supported Prostatype, and we look forward to managing your trust in the coming quarters that we expect to be quite eventful”, says Fredrik Rickman (previously Persson), CEO Prostatype Genomics.
Overview of outcome
The final outcome indicates that 202,524,736 Warrants were exercised for subscription of shares, of which 20,000,000 by offsetting claims. The degree of utilization amounted to approximately 81.0 percent. Prostatype Genomics receives proceeds of approximately SEK 7.3 million before issuing costs.
Shares and share capital
By the exercise of the Warrants, the total number of shares in Prostatype Genomics increases by 202,524,736 to 990,811,186 shares. The share capital in Prostatype Genomics increases by SEK 2,025,247.36 to SEK 9,908,111.86. Exercised Warrants have been replaced with interim shares pending the registration with the Swedish Companies Registration Office (“SCRO”). The interim shares are expected to be converted into shares approximately seven banking days after registration with the SCRO.
Advisors
Prostatype Genomics mandated Penser By Carnegie and Advokatfirman Lindahl as financial and legal advisors respectively in connection with the Rights Issue.
For further information about Prostatype Genomics, please contact:
Fredrik Rickman (previously Persson), CEO Prostatype Genomics AB
Telephone: +46 (0) 73 049 77 01.
e-mail: [email protected]
About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.
Certified Advisor
Carnegie Investment Bank AB (publ), +46 (0)73 856 42 65, [email protected]
This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person above, on 2024-04-19, at 19:25 CET.
IMPORTANT INFORMATION
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Prostatype Genomics in any jurisdiction, neither from Prostatype Genomics nor from someone else.
This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction.
This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offer of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the USA, Australia, Belarus, Canada, Hong Kong, Japan, New Zeeland, Russia, Singapore, South Africa, South Korea, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.
This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 19-04-2024 19:25 CET.
